Receipt of Delinquency Notification from Nasdaq

Rhea-AI Summary

Basel Medical Group (NASDAQ: BMGL) received a Nasdaq notice dated January 23, 2026, notifying the company that its 30-day closing bid price has fallen below the $1 minimum required for continued listing.

The company has a 180-calendar-day compliance period to regain compliance (deadline July 21, 2026) by achieving a closing bid of at least $1 for ten consecutive business days or by effecting a reverse stock split (must be completed at least ten business days before July 21, 2026). If eligible, the company may seek a second 180-day period by meeting other Nasdaq initial listing standards and notifying Nasdaq of intent to cure. Trading is not currently affected and the company is preparing a rectification plan with advisers.

Positive

• Trading remains active; no halt reported
• Company has a 180-day cure period ending July 21, 2026
• Possible additional 180-day extension if other listing standards met
• Company engaged professional advisers to prepare a rectification plan

Negative

• 30-day closing bid price is below the $1 Nasdaq minimum
• Risk of delisting if deficiency is not cured within compliance periods
• Reverse stock split may be required and could cause shareholder dilution

Key Figures

Minimum bid price: $1 per share Non-compliance period: 30 business days Initial cure period: 180 calendar days +3 more

6 metrics

Minimum bid price $1 per share Nasdaq Listing Rules requirement for continued listing

Non-compliance period 30 business days Closing bid below $1 over last 30 consecutive business days

Initial cure period 180 calendar days Compliance window to regain $1 minimum bid price

Bid price requirement 10 business days Need at least $1 closing bid for 10 consecutive business days

Reverse split deadline July 21, 2026 Reverse split must be completed 10 business days before this date

Additional cure period 180 calendar days Potential second compliance period if other standards are met

Market Reality Check

Price: $0.7999 Vol: Volume 37,765 is at 0.63x...

low vol

$0.7999 Last Close

Volume Volume 37,765 is at 0.63x the 20-day average of 60,412 ahead of this notice. low

Technical Price 0.7999 trades below 200-day MA at 2.14, reflecting a longer-term downtrend.

Peers on Argus

Pre-news move for BMGL was modest at 0.3%, while peers showed mixed performance:...

Pre-news move for BMGL was modest at 0.3%, while peers showed mixed performance: some rose (e.g., CCM, NIVF) and others fell (e.g., CCEL, MODV), indicating this Nasdaq deficiency notice is stock-specific, not a sector-wide driver.

Historical Context

1 past event · Latest: Dec 01 (Negative)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Nasdaq delinquency notice	Negative	-3.5%	Nasdaq flagged Form 20-F delinquency due to missing auditor opinion.

Pattern Detected

Limited history shows prior Nasdaq-related delinquency news coincided with a negative price reaction.

Recent Company History

This announcement adds a new Nasdaq compliance issue for Basel Medical Group, now tied to the $1 minimum bid price requirement after 30 consecutive days below threshold. Previously, on Dec 1, 2025, the company received a Nasdaq delinquency notice for its Form 20-F lacking an auditor opinion, which saw a -3.45% reaction. Alongside recent 6-K updates on acquisitions and governance, the narrative shows recurring listing-rule scrutiny while trading on Nasdaq has remained unaffected so far.

Market Pulse Summary

This announcement details a Nasdaq notice that Basel Medical Group’s shares failed the $1 minimum bi...

Analysis

This announcement details a Nasdaq notice that Basel Medical Group’s shares failed the $1 minimum bid requirement over 30 business days, triggering an initial 180-day cure period and potential additional 180 days if other standards are met. It follows a prior Nasdaq delinquency notice over the 20-F audit opinion. Investors may monitor how the company’s rectification plan, including any possible reverse stock split, interacts with its already depressed level versus the 200-day MA.

Key Terms

nasdaq listing rules, bid price, reverse stock split, market value of publicly held shares, +2 more

6 terms

nasdaq listing rules regulatory

"no longer meets the requirements under Nasdaq’s Listing Rules (the “Rules”)"

Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.

bid price financial

"to maintain a minimum bid price of $1 per share"

The bid price is the highest price a buyer is willing to pay for a share or other security at a given moment. Think of it as the offer a shopper makes at an auction — it shows what you could sell for right now if you accepted the highest buyer. Investors watch the bid because it affects how quickly a sale will execute and how much they’ll actually receive after accounting for the gap between buyer and seller prices.

reverse stock split financial

"If the Company chooses to implement a reverse stock split, it must complete"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

market value of publicly held shares financial

"meet the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

nasdaq capital market regulatory

"all other initial listing standards for The Nasdaq Capital Market, with the exception"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

delisting regulatory

"Nasdaq will provide notice that its securities will be subject to delisting."

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

AI-generated analysis. Not financial advice.

Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company’s shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq’s Listing Rules (the “Rules”) for listed securities to maintain a minimum bid price of $1 per share.

The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide you written confirmation of compliance. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration date of July 21, 2026, in order to regain compliance. In the event the Company does not regain compliance, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

The Company is currently working with its professional advisers to prepare a rectification plan to remedy the above mentioned non-compliance. Trading of the Company’s shares on Nasdaq is not currently affected by such non-compliance.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd 
+65 6291 9188 
contact@baselmedical.com 
www.baselmedical.com

FAQ

What did NASDAQ notify BMGL about on January 23, 2026?

Nasdaq notified BMGL that its 30-day closing bid price is below the $1 minimum, triggering a compliance period.

How long is BMGL's Nasdaq compliance period and what is the deadline?

BMGL has a 180-calendar-day compliance period with a deadline of July 21, 2026 to regain compliance.

What are the ways BMGL can regain Nasdaq compliance for the $1 bid rule?

BMGL can regain compliance by reaching a closing bid of $1 for 10 consecutive business days or by effecting a reverse stock split before the deadline.

Can BMGL get more time if it does not meet the $1 bid price by July 21, 2026?

Possibly; BMGL may qualify for an additional 180-day period if it meets Nasdaq market value and other initial listing standards and notifies Nasdaq of intent to cure.

Will BMGL's shares stop trading because of the Nasdaq notice?

No; trading is not currently affected according to the company.